These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 26942734

  • 1. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE, Rinella ME.
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [Abstract] [Full Text] [Related]

  • 2. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
    Tang JT, Mao YM.
    J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066
    [Abstract] [Full Text] [Related]

  • 3. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Sugimoto K, Inui H, Fukusato T.
    World J Gastroenterol; 2015 Apr 07; 21(13):3777-85. PubMed ID: 25852263
    [Abstract] [Full Text] [Related]

  • 4. State of the art: treatment of nonalcoholic steatohepatitis.
    Pearlman M, Loomba R.
    Curr Opin Gastroenterol; 2014 May 07; 30(3):223-37. PubMed ID: 24717764
    [Abstract] [Full Text] [Related]

  • 5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun 07; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 6. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S, Rustgi VK.
    Clin Liver Dis; 2016 May 07; 20(2):351-64. PubMed ID: 27063274
    [Abstract] [Full Text] [Related]

  • 7. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P, Bush H, Younossi ZM.
    Clin Liver Dis; 2017 Nov 07; 21(4):739-753. PubMed ID: 28987260
    [Abstract] [Full Text] [Related]

  • 8. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
    Ahmed A, Wong RJ, Harrison SA.
    Clin Gastroenterol Hepatol; 2015 Nov 07; 13(12):2062-70. PubMed ID: 26226097
    [Abstract] [Full Text] [Related]

  • 9. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Hung CK, Bodenheimer HC.
    Clin Liver Dis; 2018 Feb 07; 22(1):175-187. PubMed ID: 29128055
    [Abstract] [Full Text] [Related]

  • 10. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S.
    Clin Mol Hepatol; 2017 Jun 07; 23(2):103-108. PubMed ID: 28494529
    [Abstract] [Full Text] [Related]

  • 11. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T, Japanese Society of Gastroenterology, Japan Society of Hepatology.
    J Gastroenterol; 2015 Apr 07; 50(4):364-77. PubMed ID: 25708290
    [Abstract] [Full Text] [Related]

  • 12. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
    Banini BA, Sanyal AJ.
    Curr Opin Gastroenterol; 2017 May 07; 33(3):134-141. PubMed ID: 28346237
    [Abstract] [Full Text] [Related]

  • 13. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K, Stavropoulos K, Bouloukou S, Kerpiniotis G, Karagiannis A, Doumas M.
    Curr Vasc Pharmacol; 2018 May 07; 16(3):276-288. PubMed ID: 28676020
    [Abstract] [Full Text] [Related]

  • 14. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015 May 07; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 15. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
    Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L.
    Aliment Pharmacol Ther; 2014 Jan 07; 39(1):3-14. PubMed ID: 24206433
    [Abstract] [Full Text] [Related]

  • 16. Current and emerging therapies in nonalcoholic fatty liver disease.
    Kashi MR, Torres DM, Harrison SA.
    Semin Liver Dis; 2008 Nov 07; 28(4):396-406. PubMed ID: 18956296
    [Abstract] [Full Text] [Related]

  • 17. Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.
    Westfall E, Jeske R, Bader AR.
    Am Fam Physician; 2020 Nov 15; 102(10):603-612. PubMed ID: 33179890
    [Abstract] [Full Text] [Related]

  • 18. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan 15; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D, Portillo-Sanchez P, Cusi K.
    Metabolism; 2016 Aug 15; 65(8):1183-95. PubMed ID: 27301803
    [Abstract] [Full Text] [Related]

  • 20. Nonalcoholic fatty liver disease: pharmacologic and surgical options.
    Parikh N, Ahmad J.
    Gastroenterol Clin North Am; 2011 Sep 15; 40(3):541-59. PubMed ID: 21893273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.